


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I  
in which



- X denotes CH or N,  
R¹ denotes Hal, (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>Ar, CF₃, NO₂, CN, C(NH)NOH or OCF₃,  
R² denotes ~~(CH₂)<sub>n</sub>Het~~ (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF₃,  
R³, R⁴ denote H, ~~(CH₂)<sub>n</sub>CO₂R⁵~~, (CH₂)<sub>n</sub>COHet, (CH₂)<sub>n</sub>CON(R⁵)₂, (CH₂)<sub>n</sub>COO(CH₂)<sub>n</sub>Het, CHO, (CH₂)<sub>n</sub>OR⁵, (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>N(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)<sub>n</sub>NHOA, (CH₂)<sub>n</sub>N(R⁵)Het, (CH₂)<sub>n</sub>CH=N-Het, ~~(CH₂)<sub>n</sub>OCOR⁵~~, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OCF₃, (CH₂)<sub>n</sub>N(R⁵)C(R⁵)HCOOR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂COHet, (CH₂)<sub>n</sub>N(R⁵)CH₂Het, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂Het, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OR⁵, ~~(CH₂)<sub>n</sub>N(R⁵)CH₂CH₂N(R⁵)₂~~ ~~(CH₂)<sub>n</sub>N(R⁵)CH₂CH₂N(R⁵)₂~~, CH=CHCOOR⁵, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)<sub>n</sub>N(R⁵)Ar, (CH₂)<sub>n</sub>N(COOR⁵)COOR⁵, (CH₂)<sub>n</sub>N(CONH₂)COOR⁵, (CH₂)<sub>n</sub>N(CONH₂)CONH₂, (CH₂)<sub>n</sub>N(CH₂COOR⁵)COOR⁵, (CH₂)<sub>n</sub>N(CH₂CONH₂)COOR⁵, (CH₂)<sub>n</sub>N(CH₂CONH₂)CONH₂, (CH₂)<sub>n</sub>CHR⁵COR⁵, ~~(CH₂)<sub>n</sub>CHR⁵COOR⁵~~, or (CH₂)<sub>n</sub>CHR⁵CH₂OR⁵, where in each case only one of the radicals R³ or R⁴ can have the meaning H,  
R⁵ denotes H or A  
A denotes straight-chain or branched alkyl having 1 to 10 C atoms,

alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR<sup>5</sup>, OCOR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

n denotes 0, 1, 2, 3, 4 or 5, and

Hal denotes F, Cl, Br or I,

or a salt, solvate, enantiomer or racemate thereof.

2. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT<sub>2A</sub> receptor-antagonistic action.

4. (Withdrawn) A method according to claim 21, wherein the disease is psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

5. (Withdrawn) A compound according to claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.

6. (Withdrawn and Currently Amended) A compound according to claim 1, in which R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het,

~~$(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  
 $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  
 $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  
 $(CH_2)_nN(R^5)Ar$   $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  
 $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  
 $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  
 $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  
 $(CH_2)_nN(R^5)Ar$ .~~

7. (Withdrawn) A compound according to claim 1, in which  $R^4$  denotes H.

8. (Previously Presented) A compound according to claim 1, in which  $R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.

9. (Previously Presented) A compound according to claim 1, in which X has the meaning CH.

10. (Cancelled)

11. (Withdrawn) A compound according to claim 1, wherein the compound of formula I is

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1-yl)amine;

4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;

4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;


1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;

1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
 1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol;  
 [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;  
 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol;  
 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;  
 or a salt or solvate thereof.

12. (Withdrawn) A method according to claim 21, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (Currently Amended) A compound of formula I  
 in which



X denotes CH or N,  
 R¹ denotes Hal, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, CF<sub>3</sub>, NO<sub>2</sub>, CN, C(NH)NOH or OCF<sub>3</sub>,  
 R² denotes (CH<sub>2</sub>)<sub>n</sub>Het (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF<sub>3</sub>,

- $R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ ,  $(CH_2)_nCON(R^5)_2$ ,  $(CH_2)_nCOO(CH_2)_nHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$ ,  $(CH_2)_nN(R^5)Ar$ ,  $(CH_2)_nN(COOR^5)COOR^5$ ,  $(CH_2)_nN(CONH_2)COOR^5$ ,  $(CH_2)_nN(CONH_2)CONH_2$ ,  $(CH_2)_nN(CH_2COOR^5)COOR^5$ ,  $(CH_2)_nN(CH_2CONH_2)COOR^5$ ,  $(CH_2)_nN(CH_2CONH_2)CONH_2$ ,  $(CH_2)_nCHR^5COR^5$ ,  $(CH_2)_nCHR^5COOR^5$ , or  $(CH_2)_nCHR^5CH_2OR^5$ , where in each case only one of the radicals  $R^3$  or  $R^4$  can have the meaning H,
- $R^5$  denotes H or A
- A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,
- Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $OR^5$ ,  $OCOR^5$ ,  $COOR^5$ ,  $CON(R^5)_2$ , CN,  $NO_2$ ,  $NH_2$ ,  $NHCOR^5$ ,  $CF_3$  or  $SO_2CH_3$ ,
- n denotes 0, 1, 2, 3, 4 or 5, and
- Hal denotes F, Cl, Br or I,
- or a salt thereof.

14. (Withdrawn) A compound according to claim 13, wherein the

compound of formula I is

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1 -yl)amine;  
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;  
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol;  
[1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;  
2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;  
or a salt thereof.

15. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 13.

16. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD),

comprising administering to a subject in need thereof an effective amount of a compound according to claim 14.

17. (Withdrawn and Currently Amended) A compound according to claim 1, in which

$R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

$R^3$  denotes  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^4$  denotes H,

$R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

18. (Withdrawn and Currently Amended) A compound according to claim 13, in which

$R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

$R^3$  denotes  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,

$(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  
 $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,  
 $(CH_2)_nGO_2R^5$ ,  $(CH_2)_nGO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_{2,3}$ ,  
 $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  
 $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^4$  denotes H,

$R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

19. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.

20. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 18.

21. (Withdrawn) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

22. (Withdrawn) A compound according to claim 13, in which  $R^2$  denotes Het, Ar, cycloalkyl having 3 to 7 C atoms or  $CF_3$ .



23. (Currently Amended) A compound according to claim 13, in which  $R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ ,  $(CH_2)_nCON(R^5)_2$ ,  $(CH_2)_nCOO(CH_2)_nHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ , CH=N-OA,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$ ,  $(CH_2)_nN(R^5)Ar$ ,  $(CH_2)_nN(COOR^5)COOR^5$ ,  $(CH_2)_nN(CONH_2)COOR^5$ ,  $(CH_2)_nN(CONH_2)CONH_2$ ,  $(CH_2)_nN(CH_2COOR^5)COOR^5$ ,  $(CH_2)_nN(CH_2CONH_2)COOR^5$ ,  $(CH_2)_nN(CH_2CONH_2)CONH_2$ ,  $(CH_2)_nCHR^5COR^5$ ,  $(CH_2)_nCHR^5COOR^5$  or  $(CH_2)_nCHR^5CH_2OR^5$ , where in each case only one of the radicals  $R^3$  or  $R^4$  can have the meaning H, wherein, within the definition of  $R^3, R^4$ , the n is 1, 2, 3, 4 or 5.

24. (Withdrawn) A compound according to claim 23, in which  $R^2$  denotes Het, Ar, cycloalkyl having 3 to 7 C atoms or  $CF_3$ .

25. (New) A compound according to claim 1, in which  $R^3, R^4$  denote H,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ , CH=N-OA,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$ ,  $(CH_2)_nN(R^5)Ar$ ,  $(CH_2)_nCHR^5COR^5$ , or  $(CH_2)_nCHR^5CH_2OR^5$ ,

where in each case only one of the radicals  $R^3$  or  $R^4$  can have the meaning H.

26. (New) A compound according to claim 1, in which  $R^3, R^4$  denote H,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $(CH_2)_nN(R^5)Ar$ ,  $(CH_2)_nCHR^5COR^5$ , or  $(CH_2)_nCHR^5CH_2OR^5$ , where in each case only one of the radicals  $R^3$  or  $R^4$  can have the meaning H.